By a News Reporter-Staff News Editor at Biotech Week -- Abzena plc (AIM: ABZA, 'Abzena'), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into a master service agreement with one of America's leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug discovery services, will help NYU Langone's drug discovery accelerator, the Office of Therapeutics Alliances (OTA), to develop novel biopharmaceutical therapeutics (see also Abzena plc).
The first project under this master agreement centres around the development of a novel biopharmaceutical being developed by NYU OTA for the treatment of severe autoimmune disease. Abzena will provide integrated development support from its bioassay, immunology and protein engineering groups.
NYU School of Medicine is one of the USA's top-ranked medical schools. An integral part of NYU Langone Health, the School of Medicine at its core is committed to improving the human condition through medical education, scientific research, and direct patient care. Dr. Campbell Bunce, SVP, Scientific Operations, Abzena commented: "It's fantastic that our expertise and integrated offering across our biology group is being used in the development of another promising treatment. "This agreement represents another example of Abzena supporting exciting drug candidates from academic groups, utilising not just our services but also our significant biologics know-how." Dr. Nadim Shohdy, Assistant Dean and Director, Therapeutics Alliances, NYU Langone commented: "We are very excited to execute both the master agreement, and to launch this inaugural project with Abzena. "This partnership will augment NYU Langone's access to deep biologics capabilities and expertise to further enhance OTA's mission to translate the research of our faculty into therapeutic products that help patients." Notes to editors About Abzena Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and royalties on ABZENA Inside products.
Keywords for this news article include: Business, Abzena plc, Proteomics, Therapeutics, United States, Bioengineering, Medical Devices, Biopharmaceuticals, Drugs and Therapies, Health and Medicine, Protein Engineering, Biotechnology Companies, Life Sciences Companies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
(c) 2018 NewsRx LLC, source Health Newsletters